Haleon shares slide as weak cold and flu demand forces a cut to its revenue target
Summary
Haleon shares slid after targets were cut due to weak cold and flu demand, The Independent and the Evening Standard reported on Thursday 29 October, the FTSE 100 company saying revenues grew by 2.5% to £2.87 billion for the three months to September 30, compared with the same period last year. Soft demand for cough, cold and flu medicines forced the consumer healthcare giant to cut its revenue target, City A.M. reported, the firm losing more than 11 per cent in early trading, to 333p, after expecting revenue growth of between three and five per cent.
Latest: Haleon shares slid after targets were cut due to weak cold and flu demand, the company saying revenues grew by 2.5% to £2.87 billion for the three months to September 30, The Independent and the Evening Standard reported, City A.M. writing that the shares lost more than 11 per cent in early trading, to 333p.
Written automatically by an AI from the articles' headlines and descriptions. It can contain errors: follow the links to read the articles.
How it unfolded
Thursday 29 October
Haleon shares slid after targets were cut due to weak cold and flu demand, the company saying revenues grew by 2.5% to £2.87 billion for the three months to September 30, The Independent and the Evening Standard reported, City A.M. writing that the shares lost more than 11 per cent in early trading, to 333p.
- 08:39Evening Standard Haleon shares slide after targets cut due to weak cold and flu demand
- 08:39The Independent Haleon shares slide after targets cut due to weak cold and flu demand
- 05:00City A.M. Haleon shares crater as soft flu demand hits takings